10 completed, 5 recruiting, 3 withdrawn, 2 unknown. 8 Phase 2, 3 Not applicable, 2 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Withdrawn 3, Unknown 1 |
| Not applicable | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 3 | 2 | Withdrawn 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Cystinuria: new trials by email Literature Review of Cystinuria trials Research Report on Cystinuria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating Patients With Cystinuria ADV7103, Standard of Care - Cystinuria | Phase 2 / Phase 3 | Withdrawn | Advicenne Pharma | 2024-05-01 | 2024-03-12 | |
| Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children ADV7103, Placebo - Cystinuria | Phase 2 / Phase 3 | Withdrawn | Advicenne Pharma | 2024-03-01 | 2026-01-08 | |
| Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics Dapagliflozin - Cystinuria | Phase 2 | Withdrawn | University of California, San Francisco | 2023-09-01 | 2025-08-29 | |
| The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study Dapagliflozin - Cystinuria | Phase 2 | Completed | University of California, San Francisco | 10 | 2021-08-30 | 2025-10-16 |
| Registry of Thiola EC Therapy Cystinuria | Completed | NYU Langone Health | 25 | 2021-03-02 | 2024-02-29 | |
| Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria Tiopronin - Cystinuria | Phase 2 | Completed | NYU Langone Health | 10 | 2018-11-01 | 2021-12-17 |
| This Study Evaluates the Superiority of Daily Self-pH Monitorization of Lit-control®pH Meter Compared to the Monitorization of Reactive Strips (Standard of Care). Lit-control®pH Meter, Reactive strips - Cystinuria | Not applicable | Unknown | Devicare S.L. | 60 | 2018-04-09 | 2018-11-21 |
| Monogenic Kidney Stone - Genetic Testing Rare Kidney Stone Diseases | Recruiting | Mayo Clinic | 6000 | 2017-09-11 | 2026-04-13 | |
| Lipoic Acid Supplement for Cystine Stone Alpha lipoic acid, Placebo - Cystinuria | Phase 2 | Completed | Thomas Chi, MD | 50 | 2017-06-19 | 2026-04-15 |
| Bucillamine Phase 2 Trial in Patients With Cystinuria Bucillamine - Cystinuria | Phase 2 | Unknown | Revive Therapeutics, Ltd. | 30 | 2017-05-01 | 2017-05-18 |
| TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study Tolvaptan - Cystinuria | Not applicable | Completed | Caleb Nelson | 4 | 2016-10-01 | 2020-07-10 |
| Prospective Research Rare Kidney Stones (ProRKS) Hyperoxaluria, Cystinuria | Recruiting | Mayo Clinic | 220 | 2016-05-01 | 2026-08-07 | |
| Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria Potassium citrate - Cystinuria, Renal Lithiasis | Completed | European Georges Pompidou Hospital | 63 | 2015-04-02 | 2022-03-22 | |
| Health-related Quality of Life in Rare Kidney Stone Health-related Quality of Life in Rare Kidney Stone Questionnaire - Primary Hyperoxaluria, Cystinuria | Completed | NYU Langone Health | 365 | 2013-08-01 | 2022-09-02 | |
| Rare Kidney Stone Consortium Biobank Primary Hyperoxaluria, Dent Disease | Recruiting | Mayo Clinic | 2000 | 2013-05-01 | 2026-07-22 | |
| Cystine Capacity Clinical Study (CysCap) Cystinuria | Completed | NYU Langone Health | 30 | 2012-09-01 | 2018-12-03 | |
| Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria Tiopronin 1g per day, Tiopronin 2g per day, Tiopronin 3g per day - Cystinuria | Phase 4 | Completed | NYU Langone Health | 10 | 2012-06-01 | 2021-08-23 |
| National Registry of Rare Kidney Diseases Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis | Recruiting | UK Kidney Association | 35000 | 2009-11-06 | 2023-10-04 | |
| Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones Cystone, Sugar Pill (Placebo) - Cystinuria, Nephrolithiasis, Calcium Oxalate | Phase 1 / Phase 2 | Completed | Mayo Clinic | 20 | 2006-04-01 | 2016-02-04 |
| Rare Kidney Stone Consortium Patient Registry Primary Hyperoxaluria, Dent Disease | Recruiting | Mayo Clinic | 730 | 2003-07-01 | 2026-07-10 |
Showing 20 of 21. Sign in to see all of them.
Adenine phosphoribosyltransferase deficiency (6) · Dent Disease (6) · Hyperoxaluria, Primary (6) · Hyperoxaluria (4) · Kidney Calculi (4) · Nephrolithiasis (2) · Oculocerebrorenal Syndrome (2) · Atypical Hemolytic Uremic Syndrome (1) · Bartter Syndrome (1) · Calciphylaxis (1) · Cystinosis (1) · Denys-Drash Syndrome (1) · Diabetes Insipidus, Nephrogenic (1) · Fabry Disease (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (21) · Female Urogenital Diseases (21) · Female Urogenital Diseases and Pregnancy Complications (21) · Genetic Diseases, Inborn (21) · Kidney Diseases (21) · Male Urogenital Diseases (21) · Renal Tubular Transport, Inborn Errors (21) · Urogenital Diseases (21) · Urologic Diseases (21) · Renal Aminoacidurias (20) · Metabolic Diseases (7) · Nutritional and Metabolic Diseases (7) · Carbohydrate Metabolism, Inborn Errors (6) · Genetic Diseases, X-Linked (6) · Metabolism, Inborn Errors (6)
Potassium Citrate (2) · Tiopronin (2) · dapagliflozin (2) · Penicillamine (1) · Quality of Life (1) · Sodium Bicarbonate (1) · Standard of Care (1) · Sugars (1) · Thioctic Acid (1) · Tolvaptan (1) · Videotape Recording (1) · bucillamine (1) · cystone (1) · potassium bicarbonate (1)
Mayo Clinic (5) · NYU Langone Health (5) · Advicenne Pharma (2) · University of California, San Francisco (2) · Caleb Nelson (1) · Devicare S.L. (1) · European Georges Pompidou Hospital (1) · Indiana Kidney Stone Institute (1) · Revive Therapeutics, Ltd. (1) · Thomas Chi, MD (1) · UK Kidney Association (1)
United States (16) · France (3) · Iceland (3) · Belgium (2) · Canada (1) · Israel (1) · Spain (1) · United Kingdom (1)
David Goldfarb, MD (4) · David S Goldfarb, MD (2) · Caleb Nelson, MD, MPH (1) · David Sas, DO (1) · Dawn S. Milliner, M.D. (1) · James Lingeman, MD (1) · John C Lieske, M.D. (1) · John C Lieske, MD (1) · John Lieske, MD (1) · Marshall Stoller (1) · Marshall Stoller, MD (1) · Oriol Angerri, MD (1) · Stephen B. Erickson, M.D. (1)
PMID 21161651, PMID 21419606, PMID 25365230, PMID 25717071
U54DK083908 (4), P20DK100863 (1), P50DK083007 (1)